Events

Virtual AI Summit w/ Kevin Garwood and Peju Oshisanya

Panel Discussion: AI x Policy: Driving Responsible and Scalable Data Governance Best Practice – Looking Ahead at How External Stakeholders and Governmental Regulations Will Influence Data Strategy

  • Multinational companies – transferring and accessing data across borders, given different jurisdictions/laws/regulations
  • Brexit and the future of GDPR
  • European Union/US/China – what’s next in tech policy? How will it change tech investment and innovation? What does it mean for private companies?
  • Data Diversity
Speakers
  • Richard Self - Senior Lecturer in Governance of Advanced and Emerging Technologies, University of Derby
  • Eline Chivot - Senior Policy Analyst, Center for Data Innovation
  • Edwina Dunn - Co-Founder & Board Member, dunnhumby & Centre for Data Ethics & Innovation
  • Peju Oshisanya - Director – Clinical Programme Leader, Benevolent AI
  • Mike Wiley - Application CTO and VP Engineering, F5

Healthcare Track: Data Diversity Effort at BenevolentAI

→ Register here


Peju Oshisanya
AI Ethics, Data Diversity Advocate, Clinical Drug Development Leader at BenevolentAI

Peju is an innovative operational strategy expert with over 15 years wide-ranging experience relating to strategic programme leadership, planning and management of clinical trials with responsibility for global clinical programmes. She has extensive experience in working in early drug discovery and exploratory phases focused on the transition of early stage assets to clinical development. She has held leadership positions in programme management responsible for key clinical programmes and assets within Eli Lilly, Sanofi Aventis, Pfizer and Takeda. In her current role at BenevolentAI, she is responsible for driving the asset strategy to maximise the value of both early and late phase drug development programmes.

Kevin Garwood
Patient Data Manager at BenevolentAI

Kevin is a patient data manager for precision medicine activities at BenevolentAI and is responsible for managing information governance concerns for patient-level data and in identifying and acquiring clinical and –omic data sources that would support our drug discovery programmes. Kevin’s interests include bioethics, intellectual property law and better understanding the value chain that shapes the worth and applicability of health data in the field of precision medicine. Most of his work involves coordinating with stakeholders from very different parts of the company.


More Posts

You Might Also Like

Blog
Intern at BenevolentAI part I: meet our 2020 intern cohort
What impactful work did our interns get up to across Engineering, Data Science, ML and business operations this summer? Get to know them and their work in our tech internships blog.
Nov 26, 2020
News
FDA grants Emergency Use Authorisation for baricitinib in hospitalised COVID-19 patients nine months after initial hypothesis was published by BenevolentAI
BenevolentAI scientists first identified baricitinib as a potential treatment for COVID-19 in early February 2020 using Benevolent's AI tools and biomedical knowledge graph.
Nov 20, 2020
News
BenevolentAI at NeurIPS 2020: Machine Learning in Drug Discovery
BenevolentAI is happy to announce it is sponsoring NeurIPS 2020. Join us to hear about data diversity and ML applied drug discovery, and to learn about careers in the field.
Nov 17, 2020
Blog
Careers with Impact: 5 learnings from machine learning applied drug discovery
Last week, we brought together four of our exceptional colleagues for a panel discussion on careers in machine learning applied drug discovery. Here are some of our main takeaways:
Nov 17, 2020
Blog
Data published in Science Advances shows baricitinib reduces COVID-19 morbidity and mortality
Research published in Science Advances supports BenevolentAI’s AI-generated hypothesis from late January for baricitinib as a treatment for COVID-19.
Nov 13, 2020
News
Sir Nigel Shadbolt joins BenevolentAI as a non-executive director
BenevolentAI strengthens its Board with the appointment of AI pioneer Sir Nigel Shadbolt as Non-Executive Director.
Nov 3, 2020